The response to TKI therapy in CML is monitored primarily by determining the level of BCR-ABL1 mRNA transcripts in peripheral blood, normalized to a control RNA and expressed as a percentage on an International Scale (Arora and Press, 2017). The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.